



XEMPERIA®

bio-inspired diagnostics

Let us show you how
XEMPERIA can
transform breast
cancer screening.
Let's save lives!

contact@xemperia.com
www.xemperia.com

Our story

XEMPERIA, a spin-off from the University of Fribourg, pioneers breast cancer research with a focus on early detection.


Our mission is to **revolutionize** the way breast cancer is screened and detected, using a simple blood test.

The challenge

Breast cancer kills. Too many women still die of breast cancer because of inefficient screening tests. More efficient tests are needed.

Our solution

A blood test for all women to detect cancer at its earliest stage. At XEMPERIA we are developing a **revolutionary**, blood tests for early breast cancer detection. The test is **unique** in its conceptions and performance. It leverages the body's immune response to the cancer and operates on PCR platform. With our solution, we will increase breast cancer survival!



The value

The test will be the **initial screening test** for women at all ages offering sensitivity superior to mammography. A positive results will require medical imaging to confirm the lesion.


Our strategy

XEMPERIA will **license** the test to a commercial partner who will produce and sell it. This model will enable a faster and efficient market entry. XEMPERIA will gain money with royalties on the sold tests.

Market and revenues

Market entry is planned for 2028, in CH first followed by EU and USA/CA. A market penetration of 1%-3%-10% respectively will generate profits to XEMPERIA of 54-162-538 million CHF annually (30% share of sales revenue). The model shows an **exponential growth** with benefice one year after market entry.

Key metrics reflecting our future development:



Future developments

Our technology is adaptable to other pathologies, including other cancers and inflammatory diseases. This will substantially **broaden XEMPERIA's market reach** and **revenue potential**.

About us

XEMPERIA was founded in 2023 by three passionate, leaders in their respective field, that are the shareholders of the company.

The team is completed by other competences.



Curzio Ruegg
CEO

Prof. MD, breast cancer and biomarker researcher



Sarah Cattin
CTO

Technical scientific specialist



Tuto Rossi
CLO

Lawyer